Literature DB >> 1941852

Treatment of basal cell carcinoma with intralesional interferon alpha-2b.

M F Healsmith1, J Berth-Jones, A Fletcher, R A Graham-Brown.   

Abstract

We report a series of 11 basal cell carcinomas of various types treated with nine intra-lesional injections of 1.5 million units of interferon alpha-2b. The diagnosis was confirmed histologically in each case. After 3 months' follow-up six tumours had resolved both clinically and histologically. In three cases the tumour size was reduced. One tumour grew larger. Side effects were well tolerated except by one subject who was withdrawn. Those cases which responded have now been followed-up for between 12 and 26 months with no clinical or histological evidence of tumour recurrence. This is the longest period of follow-up so far reported for this novel treatment. The results are encouraging and, if maintained in future series, may indicate a useful role for interferon alpha in the management of this common cutaneous malignancy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941852      PMCID: PMC1293410          DOI: 10.1177/014107689108400907

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  11 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  The effect of intralesional interferon gamma on basal cell carcinomas.

Authors:  L Edwards; D Whiting; D Rogers; K Luck; K A Smiles
Journal:  J Am Acad Dermatol       Date:  1990-03       Impact factor: 11.527

3.  Interferon: an inducer of macrophage activation by polyanions.

Authors:  R M Schultz; J D Papamatheakis; M A Chirigos
Journal:  Science       Date:  1977-08-12       Impact factor: 47.728

4.  Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a.

Authors:  J J Grob; A M Collet; M H Munoz; J J Bonerandi
Journal:  Lancet       Date:  1988-04-16       Impact factor: 79.321

5.  The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.

Authors:  L Edwards; S B Tucker; D Perednia; K A Smiles; E L Taylor; D J Tanner; E Peets
Journal:  Arch Dermatol       Date:  1990-08

6.  Differential effect of interferon on DNA synthesis, 2-deoxyglucose uptake and ornithine decarboxylase activity in 3T3 cells stimulated by polypeptide growth factors and tumor promotors.

Authors:  T Sreevalsan; E Rozengurt; J Taylor-Papadimitriou; J Burchell
Journal:  J Cell Physiol       Date:  1980-07       Impact factor: 6.384

7.  Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor.

Authors:  C E Griffiths; J J Voorhees; B J Nickoloff
Journal:  J Am Acad Dermatol       Date:  1989-04       Impact factor: 11.527

8.  Close link between reduction of c-myc expression by interferon and, G0/G1 arrest.

Authors:  M Einat; D Resnitzky; A Kimchi
Journal:  Nature       Date:  1985 Feb 14-20       Impact factor: 49.962

9.  Recombinant gamma interferon induces HLA-DR expression on squamous cell carcinoma, trichilemmoma, adenocarcinoma cell lines, and cultured human keratinocytes.

Authors:  K Kameyama; T Tone; H Eto; S Takezaki; T Kanzaki; S Nishiyama
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 10.  Progress toward therapeutic application of interferons, 1979-1983.

Authors:  E C Borden
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

View more
  2 in total

1.  Presence of interferon regulatory factor-1 in aggressive and nonaggressive histological variants of Basal cell carcinoma specimens.

Authors:  Nurten Turhan-Haktanir; F Husniye Dilek; Yavuz Demir; Onder Sahin
Journal:  J Cutan Aesthet Surg       Date:  2010-01

2.  Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a : Evaluation of Long-Term Follow-Up Results.

Authors:  Seher Bostanci; Pelin Kocyigit; Ayşegül Alp; Cengizhan Erdem; Erbak Gürgey
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.